For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

This marks the regulator's second backing for a use of Wegovy beyond weight loss and further strengthens Novo's case that the ...

The trial results indicated minimal adverse events and no evidence of immune-mediated clearance following TX45 treatment.

Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo Nordisk’s Wegovy (semaglutide 2.4 mg) ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a ...

Tectonic Therapeutics Inc. (TECX) announced favorable Phase 1a topline data for its lead asset, TX45, a long-acting, potentially ...

Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD, discuss the use of beta-blocker therapy following acute MI ...

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial Results to be presented at the ...

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

When surveyed, many physicians said the belief that patients had adequate symptom control was why they didn’t add more meds.